Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Income from Continuing Operations of 17823000.0 for Q1 2026, down 54.78% year-over-year from 39414604.38 in Q1 2025, and up 90.28% quarter-over-quarter from 183411000.0 in Q4 2025.
Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Income from Continuing Operations for 6 consecutive years, with 17823000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 54.78% year-over-year to 17823000.0; the TTM figure through Mar 2026 stood at 264216000.0 (up 24.2% YoY), while the FY2025 annual figure was 257908000.0, up 24.56% from the prior year.
- Income from Continuing Operations grew to 17823000.0 in Q1 2026 per VRNO's latest filing, from 183411000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 45866000.0 in Q1 2022 and bottomed at 272706000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 56354235.29 across 5 years, with a median of 19150000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- Verano Holdings' Income from Continuing Operations stood at 216110000.0 in 2022, then jumped by 64.24% to 77286000.0 in 2023, then sank by 252.85% to 272706000.0 in 2024, then surged by 32.74% to 183411000.0 in 2025, then jumped by 90.28% to 17823000.0 in 2026.
- Business Quant data shows VRNO's Income from Continuing Operations at 17823000.0 in Q1 2026, 183411000.0 in Q4 2025, and 43832000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Verano Holdings | 440.28 Mn | 355.08 Mn | 99.70 Mn | -13.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.41 Mn |
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |